The following IPOs are expected to price this week:
Epizyme (EPZM), a biotech developing therapeutics for patients with genetically defined cancers, plans to raise $60 million by offering 4.3 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Epizyme would command a market value of $375 million. Epizyme, which was founded in 2007, booked $48 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol EPZM. Citi, Cowen & Company and Leerink Swann are the joint bookrunners on the deal.
Kamada (KMDA), which provides plasma-derived protein therapeutics mostly in Israel and the US, plans to raise $60 million by offering 5.6 million shares at a price range of $10.81 to $10.81. At the midpoint of the proposed range, Kamada would command a market value of $379 million. Kamada, which was founded in 1990, booked $66 million in sales over the last 12 months. The Ness Ziona, Israel-based company plans to list on the NASDAQ under the symbol KMDA. Morgan Stanley and Jefferies & Co. are the joint bookrunners on the deal. (Please note: Shares already listed on the Tel Aviv Stock Exchange under the symbol KMDA.)
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there were 6 IPO pricings. ChannelAdvisor (ECOM), which provides e-commerce platform to manage sales across multiple online channels, was the week's winner, ending up 34% from its IPO price.
